International Cancer Conference Journal最新文献

HER2-targeted therapy is changing. HER2靶向疗法正在发生变化。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-28 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00730-1

Noriomi Matsumura

引用次数: 0

A case of gastritis caused by immune checkpoint inhibitor treated with infliximab. 用英夫利昔单抗治疗免疫检查点抑制剂引起的胃炎病例。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-18 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00709-y

Shizu Itsukage, Noriko Kume, Aki Tajima, Takashi Okazaki, Koji Tsuta, Hideaki Tanizaki

引用次数: 0

SMARCA4-deficient uterine tumors in young women: response to immune checkpoint inhibitors. 年轻女性SMARCA4缺陷子宫肿瘤：对免疫检查点抑制剂的反应。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-17 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00721-2

Riku Suzui, Mana Taki, Sachiko Kitamura, Masumi Sunada, Koji Yamanoi, Ryusuke Murakami, Ken Yamaguchi, Junzo Hamanishi, Sachiko Minamiguchi, Masaki Mandai

{"title":"SMARCA4-deficient uterine tumors in young women: response to immune checkpoint inhibitors.","authors":"Riku Suzui, Mana Taki, Sachiko Kitamura, Masumi Sunada, Koji Yamanoi, Ryusuke Murakami, Ken Yamaguchi, Junzo Hamanishi, Sachiko Minamiguchi, Masaki Mandai","doi":"10.1007/s13691-024-00721-2","DOIUrl":"https://doi.org/10.1007/s13691-024-00721-2","url":null,"abstract":"SMARCA4-deficient tumors have been reported in various organs and are associated with a poor prognosis. SMARCA4-deficient undifferentiated uterine sarcoma (SDUS) was first described in 2018. Conversely, loss of SMARCA4 (BRG1) expression, as observed by immunostaining, has been observed in several cases of undifferentiated endometrial carcinoma. SDUS has considerable morphologic overlap with undifferentiated endometrial carcinoma, while there are differences in their clinicopathological features. Here, we present two cases of SMARCA4-deficient uterine tumors in patients in their 20 s: SDUS (Case 1) and undifferentiated endometrial carcinoma without SMARCA4 nuclear expression (Case 2). Using comprehensive genome profiling, we found that both cases had SMARCA4 mutations, with tumor mutation burdens of 0 and 68 Muts/Mb, respectively. Case 1 had multiple lung metastases 9 months after surgery. We treated the patients with combination of an immune checkpoint inhibitor (pembrolizumab) and a multikinase inhibitor (lenvatinib), and the response to the treatment was stable. This study presents the first report on the response to immune checkpoint inhibitor and multikinase inhibitor in SDUS.Supplementary information: The online version contains supplementary material available at 10.1007/s13691-024-00721-2.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of grade1 follicular lymphoma diagnosed by laparoscopic lymph node resection: differentiating from late lymph node recurrence of endometrial cancer. 一例通过腹腔镜淋巴结切除术确诊的一级卵泡淋巴瘤：与子宫内膜癌晚期淋巴结复发的鉴别。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-17 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00724-z

Shingo Koyama, Haruko Okamoto, Koji Yamanoi, Rin Mizuno, Masumi Sunada, Mana Taki, Ryusuke Murakami, Hiroaki Ito, Ken Yamaguchi, Junzo Hamanishi, Masaki Mandai

{"title":"A case of grade1 follicular lymphoma diagnosed by laparoscopic lymph node resection: differentiating from late lymph node recurrence of endometrial cancer.","authors":"Shingo Koyama, Haruko Okamoto, Koji Yamanoi, Rin Mizuno, Masumi Sunada, Mana Taki, Ryusuke Murakami, Hiroaki Ito, Ken Yamaguchi, Junzo Hamanishi, Masaki Mandai","doi":"10.1007/s13691-024-00724-z","DOIUrl":"https://doi.org/10.1007/s13691-024-00724-z","url":null,"abstract":"Follicular lymphoma is a common hematologic malignancy; however, it is less common among all malignant diseases and is difficult to suspect in advance due to the lack of specific clinical findings. Here, we report a case in which a late recurrence of corpus cancer was first suspected and finally diagnosed as follicular lymphoma. A 67-year-old female presented to our department with enlarged pelvic lymph nodes. She was diagnosed with breast cancer (HER2-posiotive with lymph node metastasis) and corpus cancer (endometrioid carcinoma grade 2, stage IA) 16 years prior, received definitive therapy and was followed up. A positron emission tomography scan was performed, and an accumulation of 18F-fluorodeoxyglucose (FDG) was detected in multiple lymph nodes, including the lymph nodes with no change in size or enlargement. We performed laparoscopic resection of the enlarged and FDG-accumulated lymph nodes and a pathological examination. The patient was diagnosed with follicular lymphoma (FL) grade 1 and is currently under observation at the Department of Hematology. FL can be considered when there is a discrepancy between the change in lymph node size and the degree of FDG accumulation. A pathological examination is useful for accurate diagnosis. Therefore, it is important to consider tissue collection; however, care must be taken to minimize the invasiveness of the procedure for the patient.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case report of mucinous borderline ovarian tumor with recurrence as invasive carcinoma with high copy number alterations. 一例粘液性边界卵巢肿瘤病例报告，复发为高拷贝数改变的浸润性癌。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-17 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00722-1

Emi Wakazono, Mana Taki, Koichi Watanabe, Koji Yamanoi, Ryusuke Murakami, Nobuyuki Kakiuchi, Ken Yamaguchi, Junzo Hamanishi, Sachiko Minamiguchi, Seishi Ogawa, Masaki Mandai

{"title":"A case report of mucinous borderline ovarian tumor with recurrence as invasive carcinoma with high copy number alterations.","authors":"Emi Wakazono, Mana Taki, Koichi Watanabe, Koji Yamanoi, Ryusuke Murakami, Nobuyuki Kakiuchi, Ken Yamaguchi, Junzo Hamanishi, Sachiko Minamiguchi, Seishi Ogawa, Masaki Mandai","doi":"10.1007/s13691-024-00722-1","DOIUrl":"https://doi.org/10.1007/s13691-024-00722-1","url":null,"abstract":"Mucinous borderline ovarian tumors (MBOTs) have a very low recurrence rate and a good prognosis, especially in the early stages, but some MBOTs occasionally recur with the progression to mucinous ovarian carcinomas (MOCs). Here, we present a case of MBOT that recurred as invasive MOC within 3 years. To examine the reason for the progression from MBOT to MOC, whole-exome sequencing of our case identified identical mutations and copy number alterations in KRAS, CDKN2A, and TP53 in both the MBOT and recurrent MOC. The recurrent MOC had a greater copy number alteration burden compared to the primary MBOT. These findings suggest that MBOT may have progressed to MOC via recurrence, wherein the increased burden of copy number alterations could be its key driver. It was also suggested that TP53 mutations already present in MBOT may contribute to the increased copy number alterations leading to MOC.Supplementary information: The online version contains supplementary material available at 10.1007/s13691-024-00722-1.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of trastuzumab deruxtecan rechallenge in a patient with HER2-positive metastatic breast cancer: a case report. HER2 阳性转移性乳腺癌患者使用曲妥珠单抗德鲁司坦再治疗的疗效：病例报告。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-10 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00723-0

Yuko Tanaka, Naoya Ikeda, Seiji Niho, Kazuyuki Ishida

引用次数: 0

Secondary spontaneous pneumothorax during chemotherapy with bevacizumab for cervical cancer: a case report and literature review. 宫颈癌贝伐单抗化疗期间的继发性自发性气胸：病例报告和文献综述。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-09-05 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00696-0

Shogo Nishino, Mayu Yunokawa, Yosuke Matsuura, Atsushi Fusegi, Satoki Misaka, Yoichi Aoki, Akiko Abe, Makiko Omi, Hiroyuki Kanao

{"title":"Secondary spontaneous pneumothorax during chemotherapy with bevacizumab for cervical cancer: a case report and literature review.","authors":"Shogo Nishino, Mayu Yunokawa, Yosuke Matsuura, Atsushi Fusegi, Satoki Misaka, Yoichi Aoki, Akiko Abe, Makiko Omi, Hiroyuki Kanao","doi":"10.1007/s13691-024-00696-0","DOIUrl":"https://doi.org/10.1007/s13691-024-00696-0","url":null,"abstract":"Secondary spontaneous pneumothorax (SSP) due to bevacizumab has been reported in other malignancies but not in cervical cancer. We present the case of a 57-year-old woman with stage IIIB cervical cancer who developed SSP during bevacizumab chemotherapy. Despite complete remission with cisplatin-based chemoradiotherapy, she experienced a recurrence 9 months later. A thoracoscopic surgery was performed to remove a lung nodule and bulla. Subsequently, local cervical lesion recurrence and lung metastases were noted, and paclitaxel and carboplatin combined with bevacizumab were administered. After two cycles, a grade-1 left pneumothorax occurred, attributed to bevacizumab-induced tissue fragility. The patient improved within 7 days with conservative management. Bevacizumab was discontinued, and pneumothorax did not recur. This case highlights the rare occurrence of SSP in patients with cervical cancer treated with bevacizumab and underscores the importance of appropriate management of such patients, especially those who have undergone early thoracic surgery.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464977/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of pagetoid spread of urothelial carcinoma with notable reduction achieved through enfortumab vedotin, resulting in complete surgical resection. 一例通过恩福单抗维多汀显著缩小病灶，并最终完成手术切除的尿路上皮癌的片状扩散病例。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-31 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00720-3

Kenichi Tokuoka, Katsuki Muramoto, Keigo Sakanaka, Kentaro Yoshihara, Shutaro Yamamoto, Yu Imai, Kosuke Iwatani, Kojiro Tashiro, Masaya Murakami, Tohru Harada, Takuya Hayashimoto, Miyaka Umemori, Takahiro Kimura, Tatsuya Shimomura, Fumihiko Urabe

{"title":"A case of pagetoid spread of urothelial carcinoma with notable reduction achieved through enfortumab vedotin, resulting in complete surgical resection.","authors":"Kenichi Tokuoka, Katsuki Muramoto, Keigo Sakanaka, Kentaro Yoshihara, Shutaro Yamamoto, Yu Imai, Kosuke Iwatani, Kojiro Tashiro, Masaya Murakami, Tohru Harada, Takuya Hayashimoto, Miyaka Umemori, Takahiro Kimura, Tatsuya Shimomura, Fumihiko Urabe","doi":"10.1007/s13691-024-00720-3","DOIUrl":"https://doi.org/10.1007/s13691-024-00720-3","url":null,"abstract":"Secondary extramammary Paget's disease is a rare condition associated with the contiguous extension of tumor cells from the underlying adnexal structures, genitourinary, or gastrointestinal tracts. We report the case of an 80-year-old female with a 7-year history of urothelial carcinoma who presented with erythema of the labia majora. The diagnosis was pagetoid spread of urothelial carcinoma. The patient declined surgical resection of the lesion. She underwent nine cycles of first-line platinum-based chemotherapy and received one course of pembrolizumab for metastatic urothelial carcinoma. As the lesion progressively enlarged, third-line therapy with enfortumab vedotin was initiated, which resulted in significant tumor reduction. This allowed for a successful surgical complete resection of the tumor. Enfortumab vedotin was highly effective and demonstrated dramatic efficacy for controlling extramammary Paget's disease secondary to urothelial carcinoma.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitor-associated sick sinus syndrome and cardiogenic shock. 免疫检查点抑制剂相关病窦综合征和心源性休克。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-30 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00718-x

Masatake Kitano, Makiko Yomota, Kansuke Ito, Yukio Hosomi

引用次数: 0

Limb salvage using radical combined hyperthermia and radiotherapy for myxofibrosarcoma of the lower leg in an elderly patient. 使用根治性联合热疗和放疗挽救一名老年小腿肌纤维肉瘤患者的肢体。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-30 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00719-w

Katsuhiro Esaki, Tomoya Matsunobu, Satoshi Nomoto, Yumi Shimohata, Akira Maekawa, Masato Yoshimoto

{"title":"Limb salvage using radical combined hyperthermia and radiotherapy for myxofibrosarcoma of the lower leg in an elderly patient.","authors":"Katsuhiro Esaki, Tomoya Matsunobu, Satoshi Nomoto, Yumi Shimohata, Akira Maekawa, Masato Yoshimoto","doi":"10.1007/s13691-024-00719-w","DOIUrl":"https://doi.org/10.1007/s13691-024-00719-w","url":null,"abstract":"Soft tissue sarcomas account for only 1.5% of malignant tumors in adults and are therefore challenging to treat. We present a case of myxofibrosarcoma of the lower leg in an 88-year-old woman who successfully responded to combined hyperthermia and radiotherapy. We proposed a below-knee amputation because of the spread of the lesion, but the patient opted for hyperthermia with radiotherapy. One and a half years later, the tumor partially regrew, and the regrown mass was resected with an R0 margin. Unfortunately, the patient developed a surgical site infection immediately after the resection, and a skin ulcer formed. It took about 2 years for conservative treatment to result in complete ulcer epithelization. The patient has been ambulant, and has not experienced any symptoms of local recurrence or metastasis in the two and a half years since the surgery. Although adverse events related to combined hyperthermia and radiotherapy, such as delayed wound healing, should be considered, it could be an option for the treatment of localized soft-tissue sarcoma, especially in elderly patients.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0